Life Sciences

NeoPhore

NeoPhore is focused on the discovery and development of novel small molecule therapies to treat cancer through stimulation of the immune system. NeoPhore’s drug target rationale is highly validated by genetic evidence in cancer patients and cellular models.
NeoPhore was created to exploit the first of the pipeline of selective, patient-specific drugs generated by the PhoreMost […]

Creavo Medical Technologies

We are delighted to announce that the Parkwalk Opportunities Fund has made an investment in Creavo Medical Technologies, a University of Leeds Spin-out company, as part of a £13.4 million fundraising.

The round was oversubscribed, exceeded Creavo’s funding target and was strongly supported by existing shareholders including IP Group plc, the University of Leeds, and […]

Predictimmune

, ,

We are delighted to announce that the University of Cambridge Enterprise Fund IV and the Parkwalk Opportunities Fund have closed an investment in Predictimmune Limited, a spinout company from the University of Cambridge. Predictimmune is developing prognostic tests for immune-mediated conditions to aid their management and improve patient outcomes.

Their first offering, PredictImmune-CD, will be […]

Polypharmakos

Cambridge and Kew join forces to find new antimicrobial substances in plants
The Parkwalk-managed University of Cambridge Enterprise Fund IV and Cambridge Enterprise have invested £500k in Polypharmakos Limited, a spin-out from the University of Cambridge and the Royal Botanic Gardens, Kew.
Polypharmakos’s mission is to screen natural-product sources of plant, fungal and insect origin for […]

Exonate

Exonate are developing a novel approach to modulating new vessel growth.  By controlling the balance of two contrasting forms of a protein called Vascular Endothelial Growth Factor (VEGF), they have demonstrated that they could not only treat models of angiogenic disease (eg Cancer and wet AMD) but also protect kidney and nerve cells while simultaneously […]

PsyOmics

, ,

PsyOmics  is a University of Cambridge spin-out working to improve the prevention, diagnosis and treatment of neuropsychiatric disorders.

Mental illness accounts for over 15% of the disease burden in developed countries and in England alone, mental illness costs over £51.6bn per annum.

PsyOmics aims to deliver blood based biomarker diagnostics to:

Rapidly diagnose key mental health disorders
[…]

Oxford Endovascular

Oxford Endovascular are developing a novel treatment for treating brain aneurysms. The Oxford technology uses a special laser-cut metal alloy which has a shape-memory. It can be posted into a catheter during surgery, inserted into the brain and opened up into a tiny tube mesh (‘flow diverter’) that fits into the natural shape of […]

Xerion

Xerion Healthcare seeks to commercialise Dr Helen Townley’s Research Group’s work into the use of nano-particles in cancer for therapy, imaging and drug delivery.

The small size of nano-particles means they can passively accumulate in tumours due to the enhanced permeation and retention (EPR) effect, where certain sizes of molecules accumulate more in tumour cells […]

Quethera

Quethera, a spin-out from the University of Cambridge, is a gene therapy company developing a novel treatment for glaucoma.

The company aims to deliver gene products for neuroprotectants and their receptors directly to the eye, which will provide long term neuroprotection to the retinal ganglion cells (RGC) in the eye, preventing their death and visual field loss. […]

Orthox

, , ,

Orthox is a medical device company founded to exploit FibroFix, a novel silk-based biomaterial platform, for the repair of injuries to cartilage and bone. FibroFix combines exceptional strength and resilience with a porous architecture and chemical structure similar to Fibronectin, an essential component of human cartilage. Orthox believes these properties will allow FibroFix™ to […]

Sphere Medical

Sphere’s products are used in a wide range of medical applications, enabling faster clinical decision-making and improved patient outcomes, whilst providing efficiencies that result in reduced healthcare costs.

PhoreMost

PhoreMost has developed a next-generation phenotypic screening platform called ‘Site-Seeker’ to identify the best new targets for future therapy, and crucially, how to drug them. This has the potential to significantly increase the diversity of novel therapeutics for cancer and other unmet diseases, where treatment options are currently severely limited.

PhoreMost believes it is uniquely placed […]

Fluidic Analytics

, , ,

Fluidic Analytics is developing a line of tools for the rapid, accurate, cost-effective analysis of proteins and other biomolecular species. By combining a powerful microfluidics platform

Omega Diagnostics plc

Omega Diagnostics is focused on selling a wide range of specialist products, primarily in the immunoassay, in-vitro diagnostics (IVD) market within three segments: Allergy and Autoimmune, Food Intolerance and Infectious Disease.

Horizon Discovery

,

Horizon's basic science and translational research knowledge deployed in combination with best-in-class translational genomics platforms, products and services provides meaningful solutions to the challenges of translational researchers.

Sphere Fluidics

, , , , ,

Sphere Fluidics has developed unique products for use in single cell analysis and characterisation and provides collaborative R&D services.

DefiniGEN

, , ,

DefiniGEN provides human cells to the drug discovery sector for use in lead optimization and toxicity programmes.

Reinnervate

, , ,

Reinnervate is a market leading company in the fast growing 3D cell culture market.